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Abstract
Objectives Pulmonary Langerhans cell histiocytosis (PLCH)
is a rare interstitial granulomatous disease that usually affects
young adults who are smokers. Chest computed tomography
(CT) allows a confident diagnosis of PLCH only in typical
presentation, when nodules, cavitated nodules and cysts co-
exist and predominate in the upper and middle lungs.
Methods This article includes a pictorial essay of typical and
atypical presentations of PLCH at initial chest CT. Various
appearances of PLCH are illustrated and possible differential
diagnosis is discussed.
Results PLCH can present with some aspecific features that
may cause diagnosis of the initial disease to be overlooked or
other pulmonary diseases to be suspected. In cases of nodule
presentation alone, the main differential diagnosis should
include lung metastasis, tuberculosis and other infections,
sarcoidosis, silicosis and Wegener’s disease. In cases of cysts
alone, the most common diseases to be differentiated are
centrilobular emphysema and lymphangiomyomatosis.
Clinical symptoms are usually non-specific, although a history
of cigarette smoking, coupled with the presence of typical or
suggestive findings at imaging, is key to suspecting the dis-
ease. Atypical presentations require surgical biopsy for
diagnosis.
Conclusions The radiologist should be familiar with PLCH
imaging features to correctly diagnose the disease or need for
further investigation.
Teaching Points
• PLCH is a rare interstitial smoking-related disease that
usually affects young adults.
• The typical first CTshows a mix of nodules, cavitary nodules
and cysts in the upper-middle lungs.
• Atypical appearance, either cysts or nodules alone,
mandates that other diagnoses be considered.
• Lung cystic involvement correlates with lung function
abnormalities and predicts functional decline.
• Integration of the clinical history and imaging results is key
to diagnosis.
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Introduction
Pulmonary Langerhans cell histiocytosis (PLCH) is an isolat-
ed form of Langerhans cell histiocytosis characterised by
granulomatous infiltration of the distal bronchial walls with
Langerhans cells that produce small nodules and secondarily
involve the adjacent arterioles and interstitium. PLCH is rare,
representing less than 5 % of all interstitial lung diseases of
unknown aetiology [1–3].
PLCH primarily affects young adults, but it can be found
across a wide age spectrum, with no gender predilection [2]. It
occurs almost exclusively in smokers (90–95 %), which
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causes its inclusion among smoking-related interstitial dis-
eases [4]. Despite recognition of the promoting role of ciga-
rette smoking, being a smoker rarely induces the disease. This
suggests that host-related factors, in addition to an inhaled
antigen in cigarette smoke, participate in the pathogenesis of
PLCH [5, 6].
Prognosis in PLCH is favourable, yet variable. Most pa-
tients experience a clinical and radiological remission (up to
25 %) or stabilisation (up to 50 %). In a minority of patients
(15–25 %), the disease progresses to pulmonary failure/cor
pulmonale, with end-stage disease characterised by fibrocystic
changes that completely replace the lung parenchyma [6, 7].
Lung transplantation is indicated in cases of severe respi-
ratory failure. Death can occur from pulmonary hypertension
or respiratory failure. Patient survival at 5 years post-PLCH
diagnosis is reported at 87.8 % [8]. Clinical and radiological
relapse may occur years after remission [9].
Concerning therapy, based on the evidence associating
PLCH with smoking, cessation is believed to promote disease
stabilisation and should be taken as the first intervention.
Smoking cessation generally results in regression or
stabilisation of both symptoms and radiological lesions, yet
it cannot be assumed to yield a favourable outcome in any
given patient [10, 11]. Corticosteroid use during early disease
phases is accepted for control of acute inflammation and
constitutional symptoms, but is controversial for overall treat-
ment [12]. Chemotherapy is indicated in patients with multi-
system disease or severe isolated pulmonary disease at onset
or with progressive worsening of lung function during the
disease course [6].
Consequent to disease rarity, there is a lack of longitudinal
studies on the long-term natural history of the disease and
long-term benefit of therapeutic interventions [7, 13].
Symptoms, diagnosis, and clinical management at initial
patient presentation
Upon diagnosis, patients are usually symptomatic with no
productive cough and some exertion dyspnea. Pneumothorax
can be the first manifestation of the disease in as many as 15%
of patients. Fever and other constitutional symptoms can
occur in almost a third of patients. However, PLCH can be
incidentally uncovered on radiographs in 25–30 % of
cases [2, 5]. The insidious clinical presentation and relative-
ly high percentage of asymptomatic patients can result in a
diagnosis overlooked for years. Determination of the actual
time of onset can be uncertain; it is even possible that PLCH
diagnosed at an adult age may have had its onset in childhood
(Fig. 1) [13].
Initial pulmonary function tests (PFTs) can be normal in
10–15 % of patients or demonstrate a mild, predominantly
obstructive or mixed pattern [2, 14]. Among PFTs, diffusion
capacity (DLCO) is the one most frequently compromised at
disease onset. Standard laboratory tests are non-specific and
have no diagnostic significance.
PLCH can be strongly suspected on the bases of imaging
features. Initial chest radiography can suggest the disease.
Thin collimated spiral CT completed with high spatial fre-
quency reconstruction (HRCT) has a high diagnostic accuracy
for PLCH when a combination of nodules and cysts is classi-
cally shown [15–17]. Nevertheless, because of the myriad of
possible CTappearances of PLCH, diagnosis can be challeng-
ing, if not impossible, without biopsy.
In adults, bronchoalveolar lavage (BAL) is known to
have a lower sensitivity than does parenchimal biopsy,
but it is highly indicative of PLCH when the quantity of
CD1a-positive cells is >5 % of total cells. Furthermore, it
aids the exclusion of other interstitial or infectious lung
diseases [2, 6].
Definitive diagnosis is acquired by lung biopsy generally
performed by video-assisted thoracoscopic surgery (VATS).
Histopathological diagnosis relies on identification of
Langerhans cell (LC) proliferation with terminal and respira-
tory bronchiole infiltration (Fig. 2) [2, 6, 17]. The abnormal
LC proliferation recruits other inflammatory cells to produce
brochiolocentric granulomas. Microscopic findings are gener-
ally characterised by temporal lesion heterogeneity reflective
of the granuloma evolutionary phase, which may transform
into a cavitary nodule and then into a thick- and thin-walled
cyst. Nodular cavitation reflects airspace dilatation in the
centre of granuloma due to rapid destruction of the
bronchiole wall by LC infiltration. According to the
relative predominance of cellular inflammatory granulo-
mas or fibrotic changes, the early, intermediate and late
phases may be distinguished [18].
Fig. 1 A 20-year-old woman, non-smoker, with PLCH; pulmonary cysts
at her first computed tomography (CT) examination. The patient was
treated in the neonatal period for a cutaneous form of Langerhans cell
histiocytosis that regressed completely during infancy. The cysts are
postulated to have resulted from granolomatous transformation of pul-
monary histiocytosis, possibly concurrent with the cutaneous paediatric
disease. Cysts remained stable during 10 years of follow-up
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Also in the late phase of disease, when fibrotic features
prevail, LCs may be found in small-sized granulomas
harboured in thin-walled cysts [18].
Histological demonstration of the disease is not needed if
patients present with mild symptoms, typical features on CT,
and require no medical intervention beyond smoking cessa-
tion. Nor is biopsy necessary in patients with a histological
diagnosis of extra pulmonary disease and findings highly
suggestive of PLCH on chest CT.
On the contrary, biopsy is mandatory when CT shows
unusual findings, such as if the typical lesion coexistence in
different evolutionary phases is absent. Biopsy is also neces-
sary in patients who require immunosuppressive therapy [2, 6].
Imaging features at initial patient presentation
The main diagnostic criteria of PLCH include evidence of
bronchiolocentric lesions in various features along with their
typical distribution pattern that relatively spares basal regions
(Fig. 3).
Chest radiography may show ill-defined nodules or
reticulonodular changes [16]. Pulmonary alterations are gen-
erally symmetric, predominating at the upper-middle lungs
and sparing the costophrenic angles. Initial radiographic find-
ings may be just minimally or not at all significant, smoke-
related emphysema being the only conspicuous finding.
PLCH appearance on the first CT examination depends on
the disease phase [17].
Early stages present nodular lesions corresponding to
“florid” granulomas, while more advanced stages are
evidenced by cysts and fibrotic changes (Fig. 4).
Since PLCHmay be detected during any of its evolutionary
phases, early stage features are more likely, but not exclusive-
ly, found at the first CT examination [17, 19].
The early “florid” inflammatory phase is characterised by
brochiolocentric, ill-definedmicronodules or nodules possibly
surrounded by ground-glass opacification secondary to in-
flammatory interstitial infiltration. Generally, nodules are stel-
late or peripherically irregular and vary in number and diam-
eter (1–10 mm). In a minority of cases, nodules are larger
(>1 cm). Some nodules can present faint lucent centre or be
mostly cavitary.
Cysts predominate on nodules in cases in which inflamma-
tory activity is decreased. Thick-walled cysts (>2 mm thick)
progressively transform into thin-walled cysts (<2 mm thick).
Cysts may appear round and of small dimension (<1 cm),
but in advance disease they are typically larger and of different
shapes. Irregular, bi-lobed, cloverleaf, branched or bizarre
cysts derive from further cystic dilatation and adjacent cyst
fusion. Also, paracicatrical emphysema adjacent to fibrotic
changes may appear as cystic spaces.
End-stage disease is demonstrated by a fibrocystic pattern
that maintains the typical upper- and middle-lung zone
predominance.
Less common presentation patterns include cases with few,
larger than usual, smooth-marginated or highly asymmetrical
nodules (Fig. 5). Exceptional imaging presentations, such as
alveolar consolidations, single nodules or air-fluid cystic le-
sions have been reported [20]. Centrilobular emphysema is
often found in patients with PLCH, and is likely related to the
bronchiolocentric obstructive disease itself, in addition to
being a consequence of a smoking habit [21] (Fig. 6). Other
findings that can coexist with typical PLCH lesions are those
related to smoke exposure, including emphysematous bullae,
thickening of the bronchial walls, ground-glass opacities.
Fig. 2 Low-power photomicrograph (original magnification,
haematoxylin and eosin stain) of lung tissue shows dense non-necrotising
granulomatous infiltration. The sample demonstrates well both
localisation of the lesion around a dilated terminal airway and bronchial
wall destruction by the infiltrate. The inflammatory cell infiltration also
shows an interstitial distribution (arrow) (courtesy of Dr. E. Bonacina)
Fig. 3 A 41-year-old woman with PLCH. Coronal CT image (thin MIP
reconstruction) showing typical distribution of disease: many cysts
predominating in upper andmiddle lungs fiends, with somemicronodules
(arrow); typically, basal regions are spared
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Smoking related interstitial lung diseases such as respiratory
bronchiolitis interstitial lung disease (RB-ILD) and
desquamative interstitial pneumonia (DIP) have been
described concurrent with PLCH.
The challenging diagnosis at initial patient presentation
Although the combination of nodules and cysts in various
degrees of evolution is a hallmark diagnostic sign of PLCH,
the presence of such unique lesions requires that other
diagnoses be considered [2, 17]. Table 1 summarises the most
common differential diagnosis in case of a unique pattern of
lesions presentation.
Micronodular and nodular pattern
In case of exclusively nodular disease, the principal differen-
tial diagnoses include lung metastasis, Mycobacterium and
other infections, silicosis and sarcoidosis, and Wegener’s
disease (Fig. 7).
PLCH nodules found during serial imaging examinations
in oncologic patients may be indistinguishable from metasta-
sis. In such cases, diagnosis is possible only by biopsy or on
retrospective follow-up of the disease evolution [22].
Infectious diseases, presenting with micronodular or nod-
ular patterns may occasionally have PLCH-like features [23].
A thorough medical history, coupled with an assessment of
infection risk, may direct the radiologist to the correct
diagnosis.
Fig. 5 A 34-year-old man, smoker, symptomatic for cough and fever.
Definitive diagnosis obtained by VATS performed within a month of
imaging. A 3-mm collimated CT shows scattered nodules, with asym-
metric distribution. The largest nodules measure 15–20 mm; nodular
borders are irregular or atypically smooth. Smooth linear interstitial
thickening is also evident
Fig. 6 A 38-year-old man, non-smoker, with asymptomatic PLCH and
skin involvement. Diagnosis obtained by skin lesion biopsy. BAL>5 %
CD1a+cells. HRCTscans at diagnosis show a tiny micronodularity along
with multiple areas of centrilobular emphysema
Fig. 4 Different imaging presentations of PLCH at clinical onset. Defin-
itive diagnosis obtained by VATS performed within a month of imaging. a
A 48-year-old woman, smoker, symptomatic for dry cough andmild fever.
A 3-mm collimated CT shows a pattern of early “florid” disease
characterised by numerous scattered nodules, of which almost all are
cavitated and surrounded by ground glass opacities. A consolidation area
also coexists (arrow). bA 46-year-old woman, symptomatic for dry cough
and mild fever. HRCT scans show diffuse ill-defined micronodularity,
cavitating nodules, cysts and mild interstitial thickening. c A 50-year-old
woman, smoker, symptomatic for dry cough. HRCT scans show cystic
disease with a few scattered micronodules
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The typical centrilobular distribution of micronodules in
PCLH is the main feature to differentiate PLCH from
sarcoidosis and silicosis, which also predominate at the upper
regions but are characterised by a prominent perilymphatic
distribution of nodules. Nevertheless, in isolated nodules, this
distinctive feature can be missed due to granuloma coales-
cence [24]. Another diagnostic differential criterion is the
absence of mediastinal and hilar lymph nodes in PLCH.
Early PLCH can have the same features as RB-ILD, pre-
senting as bronchiolocentric ill-defined micronodules gener-
ally associated with mild centrilobular emphysema (Fig. 8).
Fortunately, clinical management of both diseases is similar in
that smoking cessation is the most important medical
intervention.
Nodular cavitary pattern
When cavitary nodules are prominent, the main differential
diagnoses include Wegener’s granulomatosis, septic and met-
astatic nodules, cavitated Pneumocystis jiroveci lesions
(Fig. 9).
Wegener’s granulomatosis, which is also called granulo-
matosis with polyangiitis, is a necrotising vasculitis that af-
fects small- to medium-sized vessels and commonly involves
the lungs, the kidneys and upper respiratory tract. Among the
multiple presentation features, Wegener’s disease can appear
as a few, randomly distributed pulmonary nodules or, less
commonly, as centrilobular micronodularity [25]. Nodules
cavitate in up to 50 % of cases due to primary collagen
necrosis, which can make the nodules of Wegener’s granulo-
matosis look similar to those in the “florid” phase of PLCH. A
wide spectrum of laboratory abnormalities is usually found in
Wegener’s disease.
Metastatic nodular cavitation may occur in the squamous
cell type, although nodules from adenocarcinomas and sarco-
mas may infrequently do so [26]. Cavitary metastases gener-
ally display an irregular thickening of the walls, although thin-
walled nodules can be found.
Septic emboli or excavated pneumocystosis may appear
indistinguishable from PLCH nodules on CT imaging.
Table 1 Lesion presentation pat-
terns: diseases to differentiate
from PLCH
aRB-ILD respiratory bronchiolitis
interstitial lung disease, DIP
desquamative interstitial
pneumonia, LIP lymphocytic
interstitial pneumonia, HP
hypersensitivity pneumonitis
b Usually in association with
ground-glass opacities and
pulmonary changes that may
suggest the disease
Nodules/micronodules Cavitating nodules Cysts
Lung metastasis
Tuberculosis/infectious nodules
Sarcoidosis, silicosis
Wegener disease/vasculitis nodules
aRB-ILD
Wegener disease/vasculitis nodules
Lung metastasis
Septic emboli
Cavitated P. jiroveci lesions
Lymphangioleiomyomatosis
Centrilobular emphysema
UIP
Lung metastasis
LIPa,b, HPa,b, DIPa,b
Cystic fibrohistiocytic tumour
Birt Hogg Dubé syndrome
Light-chain disease
Amyloidosis
Pneumatocoeles
Fig. 7 PLCH presenting with nodular features that mimic other diseases.
a PLCH referred to metastasis: a 44-year-old woman, smoker, with a
medical history of carcinoma of cervix uteri, treated with surgery and
chemotherapy. A 3-mm collimated CT performed during oncological
follow-up shows some faint micronodules in both lungs (arrows). Defin-
itive diagnosis of PLCH obtained by VATS. b PLCHmimicking sarcoid-
osis: a 41-year-old man, smoker, with asymptomatic PLCH and skull
involvement. Diagnosis obtained by skull biopsy. A 3-mm collimated CT
shows numerous millimetric nodules. Nodules are mostly spread at the
upper and middle lung fields in a peripheral location; few are subpleuric
Insights Imaging (2014) 5:483–492 487
Differential diagnosis requires consideration when a patient is
at-risk or when constitutional symptoms are present. In either
event, confirmation by BAL or biopsy is needed.
Cystic pattern
The most common differential diagnoses in predominantly
cystic PLCH include usual interstitial pneumonia (UIP),
centrilobular emphysema, and lymphangioleiomyomatosis
(LAM) [27–29].
Diagnostic problems usually do not subsist in UIP due to
the typical laterobasal abnormalities distribution, layered ar-
rangement of cysts, intralobular interstitial thickening and
traction bronchiectasis.
Centrilobular emphysema typically appears as lucent areas
lacking distinct walls with a central centrilobular artery. Oc-
casionally, however, centrilobular emphysema may show par-
tial walls related to fibrotic peripheral changes, and vice versa,
the cyst walls of pulmonary histiocytosis may appear so thin
as to simulate emphysema (Fig. 10).
LAM affects pre-menopausal women in a sporadic form or,
most commonly, with tuberous sclerosis complex. It is a pure
cystic disease, cysts being caused by air trappingmechanism due
to smooth-muscle cell peribronchial proliferation [30]. Pneumo-
thorax is the first manifestation of LAM in up to 50%of patients.
As in PLCH, HRCT highlights thin-walled cysts. Three
features can help to distinguish LAM from PLCH: cysts have
a more regular morphology and lack the bizarre shapes typical
of advanced PLCH; cysts are randomly distributed without
Fig. 8 A 35-year-old man, smoker, with asymptomatic PLCH (chest
radiograph performed for traumatic injury). Diagnosis based on typical
lesion heterogeneity on CT imaging. a Two-millimetre collimated CT
images at initial diagnosis shows bilateral centrilobular ground-glass
nodules, thin-walled cysts and a single air-trapping zone. Upper and
middle lung are predominantly affected. b Three-millimetre collimated
CT after 5 months of smoking cessation shows almost complete resolu-
tion of the centrilobular nodularity while thin-walled cysts remain
unchanged
Fig. 9 Diseases requiring differentiation from PLCH when cavitary
nodules are the main presenting feature. a Septic pulmonary embolism
in a critically ill patient with endocarditis. A 3-mm collimated CT scan
demonstrates both a few solid and cavitary scattered nodules, compatible
with haematogenous seeding; some consolidative opacities are also pres-
ent on the left lung. b Biopsy-confirmed Wegener’s disease in a 67-year-
old man with systemic symptoms and dry cough. A 3-mmCTscan shows
two pulmonary nodules (arrows), one of which is cavitated, bilateral
bronchiectatic changes and an ill-defined ground glass opacity in the
right lung. c Cavitating metastasis in a 68-year-old man with hilar
cholangiocarcinoma at onset. A 3-mm collimated CT scan reveals nu-
merous solid and cavitary small nodules, showing relatively thin walls
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sparing the costophrenic angles; parenchymal nodules are less
frequent, although reported in a small number of cases. De-
spite these differences, pulmonary findings can be confound-
ing between the two diseases, such that biopsy is mandatory in
young females with a pure cystic pattern at onset/initial
presentation (Fig. 11).
The cysts of PLCH should be differentiated from the
pneumatocoeles which accompany primary pulmonary
Fig. 10 A 68-year-old woman, smoker, symptomatic with excertional
dyspnea. Definitive diagnosis obtained by VATS performed at time of b.
a A 1-mm collimated CT shows focal air spaces that appear as emphy-
sema. A faint micronodule is also present (arrow). b A 1-mm collimated
CT 9 months after a with no smoking cessation demonstrates transfor-
mation and progression of focal air spaces that now appear as irregular
cystic lesions surrounded by ground-glass opacities. Some scattered
nodules coexist. c At 3-year follow-up, HRCT scans show cystic disease
progression with some non-walled cysts. Parenchymal infiltrates have
regressed
Fig. 11 Cystic PLCH compared with LAM a, b A 22-year-old
woman hospitalised for pneumothorax. Medical history was nega-
tive for respiratory disease. Definitive diagnosis of PLCH obtained
by VATS performed within a month of imaging. HRCT scans show
numerous thin-walled cysts of mostly ovoid and polygonal shape
with a nearly imperceptible predominant craniocaudal distribution.
Persistence of a small pneumothorax is shown. c, d Biopsy-confirmed
LAM in two young female patients. A 3-mm collimated CT scan shows
diffuse (c) and mild (d) pulmonary involvement of thin-walled cysts
randomly distributed throughout both lungs, with some faint
micronodules (arrows) (compare d with Fig. 1)
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infections (such as Staphylococcus aureus and P. jiroveci) and
that usually resolve with treatment of the underlying infection.
Cystic PLCH must also be differentiated from rare
cystic lung diseases, which are mostly associated with
peculiar clinical presentations [27, 28, 31]. Lung cysts
found in amyloidosis and light-chain deposition disease
(LCDD) generally occur in association with multiple
myeloma or macroglobulinaemia. In inherited Birt-
Hogg-Dubé syndrome, thin walled pulmonary cysts are
characteristically found in association with facial papules
and an increased risk of developing renal tumours [31] .
Rarely, pulmonary metastasis can be pure cystic in tumours
of epithelial origin and, less frequently, in sarcomas. More-
over, cystic PLCH must be differentiated from the rare cystic
fibrohistiocytic tumour, both in the primary and in the sec-
ondary forms. Pulmonary cysts of this tumour also result from
pulmonary nodule transformation [32]. Histological assess-
ment is required for diagnosis.
Scattered cysts can be found in several interstitial lung
diseases (ILDs) like lymphocytic interstitial pneumonia
(LIP), hypersensitivity pneumonitis (HP) and desquamative
interstitial pneumonia (DIP). Diagnosis of these diseases is
generally suggested by the typical association of cysts with
ground-glass opacities and characteristic pulmonary changes.
Moreover, LIP usually occurs with lympho-proliferative or
autoimmune disorders, typically representing the most com-
mon lung pathology in Sjogren syndrome.
Reticular pattern
PLCH may rarely present prominent reticular interstitial
changes that appear as multiple interlacing lines in a net-like
arrangement [18]. Linear opacities are fine thickness and
generally coexist with a few small nodular or cystic changes.
In these cases, diagnosis of PLCH require careful search of the
characteristic lesions of the disease (Fig. 12).
Prognostic implication of first CT imaging
A strong correlation exists between disease histopathological
inflammatory activity and the different phase patterns shown
by CT imaging. The early “florid” phase corresponds to the
Fig. 12 A 34-year-old woman non-smoker with PLCH symptomatic for
dry cough. Definitive diagnosis obtained by VATS performed within a
month of imaging studies. a, b HRCT images at diagnosis shows ill-
defined micronodularity associated with predominant reticular and min-
imal bronchiectatic changes. No basal regions sparing
Fig. 13 A 61-year-old woman, smoker, with asymptomatic PLCH and
bone involvement. Diagnosis obtained by scapular biopsy. a A 3-mm
collimated CT demonstrates nodular infiltrates with irregular borders.
Some minimal faint cysts are also appreciable (arrow). b A follow-up
CT scan 6 months post-diagnosis shows almost complete regression of
pulmonary nodules. Improvement occurs with smoking reduction, but
not cessation
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most active inflammation and has potential for regression
(Fig. 13). In fact, solid and cavitary nodules may regress or
resolve completely, while cysts infrequently show improve-
ment on follow-up CT studies [33]. Generally, recurrent pneu-
mothorax implies a negative evolution of the disease [2].
The extent of lung cystic involvement at first CT examina-
tion correlates with pulmonary function abnormalities at pre-
sentation and has a predictive value for later development of
functional impairment. Specifically, severe cystic changes at
onset correlate with risk of a rapid decline until eventual
respiratory insufficiency [14, 34].
Patients with a predominant cystic pattern at onset are still
believed to benefit from long-term follow-up, although the
utility of serial CT during the course of the disease is presently
debated [14, 17, 34]. Functional tests seem to be better pre-
dictors of prognosis relative to imaging [35]. In fact, cyst
progression shown by follow-up CT studies is associated,
but does not anticipate, the decline of functional tests [36].
Both improvement or progression of pulmonary lesions
occur during a few months (14–22 m).
Conclusions
PLCH is a rare disease whose elementary lesion is a
bronchiolocentric-evolving granuloma. A history of cigarette
smoking, coupled with suggestive findings at radiographic
imaging, is key to suspect the disease. At diagnosis, symptoms
and functional tests are non-specific, while CT may be dis-
tinctive, showing lesions corresponding to the various evolu-
tionary aspects of the disease. Typical cases are characterised
by the association of nodules, cavitary nodules and cystic
lesions. However, differential diagnosis can be challenging
when CT shows unique lesions that can mimic other diseases.
Knowledge of the different CT features at presentation
helps to determine the diagnosis of PLCH correctly or to
consider PLCH among other diseases and thus guide the
diagnostic approach.
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